Compare KRNY & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | BWAY |
|---|---|---|
| Founded | 1884 | 2003 |
| Country | United States | Israel |
| Employees | 549 | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.2M | 547.7M |
| IPO Year | 2014 | 2011 |
| Metric | KRNY | BWAY |
|---|---|---|
| Price | $9.18 | $12.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $10.67 | ★ $19.27 |
| AVG Volume (30 Days) | ★ 401.0K | 77.2K |
| Earning Date | 10-22-2026 | 11-10-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | ★ 35.71 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $11.95 | $32.42 |
| Revenue Next Year | $11.09 | $23.40 |
| P/E Ratio | ★ $16.04 | $81.98 |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $6.23 | $11.77 |
| 52 Week High | $10.24 | $26.63 |
| Indicator | KRNY | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 32.03 | 31.45 |
| Support Level | $9.05 | $11.90 |
| Resistance Level | $9.74 | $14.83 |
| Average True Range (ATR) | 0.19 | 0.55 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 9.95 | 0.61 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income from their clients.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.